Literature DB >> 32032654

Gut microbiota differences between healthy older adults and individuals with Parkinson's disease: A systematic review.

Nathan D Nuzum1, Amy Loughman2, Ewa A Szymlek-Gay3, Ashlee Hendy3, Wei-Peng Teo4, Helen Macpherson3.   

Abstract

The 'Dual Hit' hypothesis, stating that Parkinson's disease (PD) begins via olfactory pathways and the gut, and the gastrointestinal symptoms PD individuals face, have largely driven the interest of the gut's involvement in PD. Studies have since observed gut microbiota differences between PD groups and controls, with these alterations potentially relating to PD pathophysiology. However, differences in the studies' methodologies precludes unanimity on the relationships of gut microbiota to PD. Thirteen observational case-control studies investigating gut microbiota in PD and controls were reviewed to assess how microbiota abundance and diversity relates to PD. Nine studies showed butyrate producing gut microbiota had lower abundances in PD compared to controls. Three studies reported α-diversity was higher, with one reporting it was lower, in PD compared to controls. Given most studies show abundance, not diversity, differences of butyrate producing bacteria between groups, we propose abundance differences are more associated with PD than microbiota diversity. As current research is observational, investigating how specific bacteria and their metabolites may alter throughout PD progression is warranted.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Alpha-diversity; Beta-diversity; Butyrate; Cognition; Microbiota-gut-brain axis; Motor-symptoms; Non-motor symptoms; Short chain fatty acid

Year:  2020        PMID: 32032654     DOI: 10.1016/j.neubiorev.2020.02.003

Source DB:  PubMed          Journal:  Neurosci Biobehav Rev        ISSN: 0149-7634            Impact factor:   8.989


  23 in total

1.  Butyrate Protects Against Salsolinol-Induced Toxicity in SH-SY5Y Cells: Implication for Parkinson's Disease.

Authors:  Bruk Getachew; Antonei B Csoka; Amna Bhatti; Robert L Copeland; Yousef Tizabi
Journal:  Neurotox Res       Date:  2020-06-22       Impact factor: 3.911

Review 2.  Gastrointestinal Dysfunction in Parkinson's Disease.

Authors:  Delaram Safarpour; Kaveh Sharzehi; Ronald F Pfeiffer
Journal:  Drugs       Date:  2022-01-25       Impact factor: 9.546

3.  Gut microbial metabolites in Parkinson's disease: Association with lifestyle, disease characteristics, and treatment status.

Authors:  Robin M Voigt; Zeneng Wang; J Mark Brown; Phillip A Engen; Ankur Naqib; Christopher G Goetz; Deborah A Hall; Leo Verhagen Metman; Maliha Shaikh; Christopher B Forsyth; Ali Keshavarzian
Journal:  Neurobiol Dis       Date:  2022-05-30       Impact factor: 7.046

4.  Dual-Hit Model of Parkinson's Disease: Impact of Dysbiosis on 6-Hydroxydopamine-Insulted Mice-Neuroprotective and Anti-Inflammatory Effects of Butyrate.

Authors:  Carmen Avagliano; Lorena Coretti; Adriano Lama; Claudio Pirozzi; Carmen De Caro; Davide De Biase; Luigia Turco; Maria Pina Mollica; Orlando Paciello; Antonio Calignano; Rosaria Meli; Francesca Lembo; Giuseppina Mattace Raso
Journal:  Int J Mol Sci       Date:  2022-06-07       Impact factor: 6.208

5.  Differences in Alpha Diversity of Gut Microbiota in Neurological Diseases.

Authors:  Zhuoxin Li; Jie Zhou; Hao Liang; Li Ye; Liuyan Lan; Fang Lu; Qing Wang; Ting Lei; Xiping Yang; Ping Cui; Jiegang Huang
Journal:  Front Neurosci       Date:  2022-06-28       Impact factor: 5.152

6.  Intestinal Microbes in Patients With Schizophrenia Undergoing Short-Term Treatment: Core Species Identification Based on Co-Occurrence Networks and Regression Analysis.

Authors:  Min Xiang; Liqin Zheng; Daoshen Pu; Feng Lin; Xiaodong Ma; Huiqian Ye; Daoqiong Pu; Ying Zhang; Dong Wang; Xiaoli Wang; Kaiqing Zou; Linqi Chen; Yong Zhang; Zhanjiang Sun; Tao Zhang; Guolin Wu
Journal:  Front Microbiol       Date:  2022-06-17       Impact factor: 6.064

Review 7.  Genetic and Environmental Factors in Parkinson's Disease Converge on Immune Function and Inflammation.

Authors:  Elizabeth M Kline; Madelyn C Houser; Mary K Herrick; Philip Seibler; Christine Klein; Andrew West; Malú G Tansey
Journal:  Mov Disord       Date:  2020-12-14       Impact factor: 10.338

Review 8.  Novel Pharmacotherapies in Parkinson's Disease.

Authors:  Yousef Tizabi; Bruk Getachew; Michael Aschner
Journal:  Neurotox Res       Date:  2021-05-18       Impact factor: 3.911

9.  To the Gut Microbiome and Beyond: The Brain-First or Body-First Hypothesis in Parkinson's Disease.

Authors:  Nathan D Nuzum; Amy Loughman; Ewa A Szymlek-Gay; Wei-Peng Teo; Ashlee M Hendy; Helen Macpherson
Journal:  Front Microbiol       Date:  2022-03-30       Impact factor: 5.640

Review 10.  Gut Microbial Metabolites in Parkinson's Disease: Implications of Mitochondrial Dysfunction in the Pathogenesis and Treatment.

Authors:  Yixuan Liang; Li Cui; Jiguo Gao; Mingqin Zhu; Ying Zhang; Hong-Liang Zhang
Journal:  Mol Neurobiol       Date:  2021-04-06       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.